CClinicalTrials.gg
Status unknownNCT04094636Updated Feb 15, 2022

Physical Training During Hospital Admission With Community-Acquired Pneumonia

An interventional study of In-bed cycling and Exercise booklet in Community-acquired Pneumonia, sponsored by Nordsjaellands Hospital. Status unknown at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-15.

Sponsored by Nordsjaellands Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Apr 2019, registered Sep 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the effect of standard usual care combined with daily supervised physical training during hospitalization with community-acquired pneumonia (CAP) compared to standard usual care alnone.

Read the detailed description

Community-acuired pneumonia (CAP) is a leading cause of hospitalization worldwide. Despite increased focus on mobilization, hospitalization is associated with bed rest. Bed rest with low levels of physical activity leads to functional deline as well as increased risk of complications.

This study is a randomized controlled trial, which investigates the effect of standard usual care combined with daily supervised physical training in patients hospitalized with CAP compared to standard usual care alone.

02

Conditions studied

  • Community-acquired Pneumonia

Browse trials for

Keywords

  • Physical training
03

In context

Pneumonia

2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.

This study's planned enrollment of 210 is above the median of 106 across 1,247 interventional studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

Nordsjaellands Hospital is the lead sponsor of 88 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients 18 years of age or older admitted to hospital with CAP defined as a new infiltrate on chest X-ray/CT and minimum one of the following symptoms: temperature \<35˚C or ≥38˚C, cough, pleuritic chest pain, dyspnea, or focal chest signs on auscultation.
  • Patients should have an expected admission length of ≥72 hours.
  • Patients should be able to move their legs.

Exclusion criteria

Exclusion Criteria:

  • Patients unable to give written consent.
  • Hospital admission within the last 14 days.
  • Severe immunosuppression (cancer chemotherapy ≤28 days, neutropenia ≤1000 cells/μL, ≥20 mg prednisolone-equivalent/day >14 days or other immunosuppressive drugs, HIV infection, former transplant).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • No intervention
    No intervention: Control

    Control group

  • Experimental
    In-bed cycling

    Supervised in-bed cycling

    Behavioral: In-bed cycling

  • Experimental
    Exercise booklet

    Supervised physical training with exercises from exercise booklet

    Behavioral: Exercise booklet

Interventions

  • BehavioralIn-bed cycling

    Patients will daily perform 30 min of supervised in-bed cycling

  • BehavioralExercise booklet

    Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet

06

What researchers measure

Primary outcomes

  1. Length of hospital stay

    Number of stays in hospital

    Time frame: From admission until discharge (an average of 5 days)

Secondary outcomes

  1. Readmissions Number of readmissions

    Time-to-event within 3-months from discharge

    Time frame: 3-months from discharge

  2. Mortality

    Time-to-event within 6-months from discharge

    Time frame: 6-months from discharge

  3. Changes in total lean mass

    Dual-energy x-ray absorptiometry scans

    Time frame: Day 1, day 5, discharge, 1- and 3-months from discharge

  4. Changes in total fat mass

    Dual-energy x-ray absorptiometry scans

    Time frame: Day 1, day 5, discharge, 1- and 3-months from discharge

  5. Changes in total fat-free mass

    Bioelectrical impedance analysis

    Time frame: Day 1, day 5, discharge, 1- and 3-months from discharge

  6. Health-related quality of life

    Scoring from -0.624 to 1.000 on the 5-level EQ-5D version (EQ-5D-5L) questionnaire (Danish version), with higher score indicating better health-related quality of life

    Time frame: Day 1, discharge, 1-, 3- and 6-months from discharge

  7. Activities of daily living

    Scoring from 0 to 100 on the Barthel Index for Activities of Daily Living (ADL) with higher score indicating greater independence.

    Time frame: Day 1, discharge, 1 month from discharge and 3 months from discharge

  8. Muscle strength

    Hand grip strength test

    Time frame: At day 1, day 5, discharge, 1- and 3-months after discharge

  9. Functional ability

    30-sec chair stand test

    Time frame: Day 1, day 5, discharge, 1- and 3-months after discharge

  10. Systemic inflammation

    Pro- and anti-inflammatory cytokine concentrations measured in pg/ml (IL-6, IL-8, IL-18, IL-1a, IL-10, TNF-alpha)

    Time frame: Daily during admission (day 0 to 5), 1- and 3-months after discharge

  11. Physical activity monitoring

    AX3 accelerometers

    Time frame: During admission (up to 7 days), 7 days from discharge, 7 days from 1- and 3 months follow-up

Other outcomes

  1. Self-reported physical activity (PA) level

    3 groups of PA level (high, medium, low) are established based on the scoring of the international physical activity questionnaire (IPAQ). * High PA level: Vigorous-intensity activity on at least 3 days and accumulating a minimum of 1500 MET-minutes/week OR 7 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum of 3000 MET-minutes/week * Medium PA level: 3 or more days of vigorous-activity of at least 20 minutes/day OR 5 or more days of moderate-intensity activity or walking of at least 30 minutes/day OR 5 or more days of any combination of walking, moderate-intensity or vigorous-intensity activities achieving a minimum of 600 MET-min/week. * Low PA Level: No activity is reported OR some activity is reported but not enough to meet criteria for high or medium PA level group.

    Time frame: Answered on day 1, 1-, 3- and 6 months after discharge

  2. Glucose metabolism

    Blood samples drawn during an oral glucose tolerance test

    Time frame: Day 1, 1- and 3-months from discharge

  3. Scoring on the Charlson Comorbidity Index to predict 10-year survival

    Scale ranges from 0 to 33 points to predict he 10-year mortality for patients with a range of comorbid conditions

    Time frame: Day 1

  4. HbA1c

    To assess the average blood glucose levels over the previous 3 months

    Time frame: Day 1, 1- and 3-months after discharge

07

Study locations

1 of 1 sites recruiting
  • Department of Pulmonary and Infectious Diseases, Nordsjællands Hospital
    Hillerød, 3400, Denmark
    Recruiting
08

References and documents

Publications

  • Ryrso CK, Faurholt-Jepsen D, Ritz C, Pedersen BK, Hegelund MH, Dungu AM, Sejdic A, Lindegaard B, Krogh-Madsen R. The impact of physical training on length of hospital stay and physical function in patients hospitalized with community-acquired pneumonia: protocol for a randomized controlled trial. Trials. 2021 Aug 28;22(1):571. doi: 10.1186/s13063-021-05503-2. PubMed 34454594 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04094636
Lead sponsor
Nordsjaellands Hospital
Responsible party
Camilla Koch Rysoe (Principal investigator, MSc, Nordsjaellands Hospital) — Principal investigator
First posted
Sep 19, 2019
Start date
Apr 1, 2019
Primary completion
Apr 1, 2022 (estimated)
Completion
Oct 1, 2022 (estimated)
Last update
Feb 15, 2022

Study contacts

Camilla Ryrsø, MSc
Contact
camilla.koch.ryrsoe.01@regionh.dk
+4548293261
Birgitte Lindegaard, MD, PhD
study director · Department of Pulmonary and Infetious Diseases, Nordsjællands Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion